Monitor for additional funding announcements and stockholder approval for warrant issuance, as the company remains at risk of delisting from Nasdaq and may need further capital to continue operations beyond August 2026.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 23 $0.2870entry
- T+1 · 7mo ago +9.76%α +8.97% · $0.3150
- T+5 · 7mo ago −10.80%α −12.28% · $0.2560
- T+20 · 6mo ago −4.88%α −9.51% · $0.2730
- T+60 · 4mo ago +380.84%α +375.82% · $1.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Outlook Therapeutics is raising $4.65 million through a registered offering of 16.1 million shares at $0.31 per share, accompanied by warrants to purchase an equal number of shares at the same price. The proceeds will extend the company's cash runway into August 2026, but substantial doubt remains about its ability to continue as a going concern. The company also amended existing warrants to lower their exercise price from $2.26 to $0.31, reflecting financial distress.
Key Facts
- Offering 16,129,033 shares at $0.31 per share, raising gross proceeds of $5 million
- Concurrent private placement of warrants to purchase 16,129,033 shares at $0.31 per share
- Net proceeds estimated at $4.65 million after placement agent fees
- Company has substantial doubt about its ability to continue as a going concern
- Cash runway extended to August 2026, but additional funding will be required
- Amended existing warrants from $2.26 to $0.31 exercise price, indicating financial distress
- Common stock trading at $0.32, below $1.00 Nasdaq listing requirement
Financial Impact
Raises $4.65 million in net proceeds, but results in significant dilution to existing shareholders
Risk Factors
- Substantial doubt about the company's ability to continue as a going concern
- Risk of delisting from Nasdaq due to share price below $1.00 minimum
- Significant dilution from the offering and warrant amendments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-047242 |
| Document: 0001104659-26-047242-index-headers.html | 0001104659-26-047242 |
| Document: 0001104659-26-047242-index.html | 0001104659-26-047242 |
| Document: 0001104659-26-047242.txt | 0001104659-26-047242 |
Track record
37 reports on OTLK
12 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 17 of 22 went positive at some point.
Filters
- Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
- Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
- Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
- Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers